Table 2 Sex difference of DHA-Na metabolism in liver microsome after inhibitors treatment
From: Sex differences in CYP450-based sodium dehydroacetate metabolism and its metabolites in rats
Group | Concentration | DHA-Na metabolism inhibition rate (%) | |
|---|---|---|---|
Male | Female | ||
Control | — | — | — |
Furafylline (CYP1A2 inhibitor) | 50 | 23.48 ± 3.61 | 33.93 ± 3.83* |
40 | 17.64 ± 2.68 | 24.70 ± 3.49* | |
20 | 12.23 ± 1.88 | 16.52 ± 3.84 | |
Ketoconazole (CYP3A2 inhibitor) | 50 | 15.40 ± 1.96 | 20.77 ± 3.72** |
40 | 12.71 ± 1.35 | 16.97 ± 2.98* | |
20 | 5.70 ± 0.74 | 7.62 ± 1.31 | |
Quinidine (CYP2D1 inhibitor) | 50 | 6.81 ± 0.82 | 12.42 ± 2.64** |
40 | 4.81 ± 0.59 | 10.41 ± 2.03** | |
20 | 4.14 ± 0.62 | 6.74 ± 1.26 | |
Ticlopidine (CYP2C11 inhibitor) | 50 | 2.60 ± 0.41 | 3.69 ± 0.72 |
40 | 1.59 ± 0.37 | 1.94 ± 0.35 | |
20 | 0.04 ± 0.11 | 0.30 ± 0.17 | |
Chlomethiazole (CYP2E1 inhibitor) | 50 | 1.60 ± 0.21 | 2.51 ± 0.53 |
40 | 0.91 ± 0.13 | 1.49 ± 0.22 | |
20 | 0.48 ± 0.18 | 1.22 ± 0.32 | |
